Safety, Feasibility, and Acceptability of the MINERVA Voice Conversational Agent for Emergency Department History-Taking
Public ClinicalTrials.gov record NCT07877883. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Feasibility and Acceptability of a Voice Conversational Agent in the Emergency Department
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study evaluates whether an artificial intelligence (AI) conversational agent called MINERVA (Medical Interface for Navigating the Emergency Room with Voice Assistance) can safely and feasibly gather medical histories from emergency department (ED) patients and produce accurate summaries. The main questions it aims to answer are: Can an AI conversational agent gather and summarize patient histories in the emergency department? Are the resulting summaries accurate? Do they capture essential clinical information? Can an AI agent overseeing these conversations independently identify red-flag symptoms that may need time-sensitive clinical interventions? Adult ED patients interact with MINERVA via either voice chat or typing on a keyboard. MINERVA asks them questions about their symptoms and generates a summary which the patients review for accuracy. MINERVA reviews the conversation for clinical red flags that suggest urgent evaluation is required. Participants fill out a survey providing feedback on their experience. The summary is not saved in the medical record and clinical care is not affected. Physician reviewers will evaluate the safety, accuracy, and clinical value of the MINERVA interview transcripts and summaries using standardized rubrics, including whether MINERVA was correct in identifying red-flag symptoms that may need time-sensitive clinical interventions.
Study identification
- NCT ID
- NCT07877883
- Recruitment status
- Enrolling by invitation
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 250 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 1, 2026 (Estimated)
- Primary completion
- Jan 1, 2027 (Estimated)
- Completion
- Feb 1, 2027 (Estimated)
- Last update posted
- Oct 16, 2026
2026 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07877883, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 16, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07877883 live on ClinicalTrials.gov.